Alan P. Skarbnik, MD, Novant Health Cancer Institute
Advertisement
Articles by Alan P. Skarbnik, MD, Novant Health Cancer Institute
Advertisement
Latest Updated Articles
Therapeutic Sequencing in Relapsed/Refractory CLLPublished: January 8th 2021 | Updated:
Allogeneic Transplantation for CLLPublished: January 8th 2021 | Updated:
Frontline CLL Treatment: Addressing Unmet NeedsPublished: January 8th 2021 | Updated:
Selecting Frontline Therapy to Treat CLLPublished: January 8th 2021 | Updated:
Frontline CLL Treatment With Fixed-Duration RegimensPublished: January 8th 2021 | Updated:
Minimal Residual Disease in CLLPublished: January 8th 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
Orca-T With Reduced-Intensity Conditioning Yields Robust Efficacy in Hematologic Malignancies
4
TRX103 Tr1 Cell Therapy Shows Manageable Safety and Dose-Dependent Kinetics After HLA-Mismatched HCT in Hematologic Malignancies
5